X0306 4 2013-07-25 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532218 Patel Sanj K 33 HAYDEN AVE LEXINGTON MA 02421 true true false false President & CEO Common Stock 286 I Held by Abbey Road Investment Group Common Stock 2013-07-25 4 M false 8251 0.95 A 9282 D Common Stock 2013-07-25 4 M false 3664 0.95 A 12946 D Common Stock 2013-07-25 4 M false 20000 1.7 A 32946 D Common Stock 2013-07-25 4 S false 14711 48.73 D 18235 D Common Stock 2013-07-26 4 M false 35308 3.52 A 53543 D Common Stock 2013-07-26 4 M false 16882 1.7 A 70425 D Common Stock 2013-07-26 4 S false 52190 47.91 D 18235 D Common Stock 2013-07-26 4 S false 17204 48.31 D 1031 D Common Stock 2013-07-29 4 M false 15895 3.52 A 16926 D Common Stock 2013-07-29 4 S false 15895 47.39 D 1031 D Stock Option (Right to Buy) 0.95 2013-07-25 4 M false 8251 0 D 2019-07-01 Common Stock 8251 0 D Stock Option (Right to Buy) 0.95 2013-07-25 4 M false 3664 0 D 2019-12-15 Common Stock 3664 6106 D Stock Option (Right to Buy) 1.7 2013-07-25 4 M false 20000 0 D 2021-05-25 Common Stock 20000 73321 D Stock Option (Right to Buy) 3.52 2013-07-26 4 M false 35308 0 D 2018-09-24 Common Stock 35308 96714 D Stock Option (Right to Buy) 1.7 2013-07-26 4 M false 16882 0 D 2021-05-25 Common Stock 16882 56439 D Stock Option (Right to Buy) 3.52 2013-07-29 4 M false 15895 0 D 2018-09-24 Common Stock 15895 80819 D The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2012. The stock option granted the reporting person an option to purchase 396,070 Shares. 25% of such Shares vested and became exercisable on 07/01/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. The stock option granted the reporting person an option to purchase 117,220 Shares. 25% of such Shares vested and became exercisable on 09/25/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. The stock option granted the reporting person an option to purchase 108,052 Shares. 25% of such Shares vested and became exercisable on 5/25/2012, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $48.52 to $49.22. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The stock option granted the reporting person an option to purchase 132,022 Shares. 25% of such Shares vested and became exercisable on 06/23/2009, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $47.44 to $48.29. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $47.52 to $48.51. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $46.90 to $47.82. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Stephen F. Mahoney, Attorney-in-Fact 2013-07-29